Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Analgesic Efficacy and Safety of Desvenlafaxine in Patients With Herpes Zoster
Sponsor: Beijing Tiantan Hospital
Summary
Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia. Although early antiviral therapy limits viral replication, its analgesic effect is insufficient, and many patients experience inadequate relief despite stepwise use of non-opioids and opioids. Recent attention has focused on the potential role of antidepressants, which have central antinociceptive property and may offer analgesic benefits by modulating central nervous system pain pathways through increased serotonin and norepinephrine availability. Therefore, investigators hypothesize that desvenlafaxine may effectively reduce the severity of HZ pain without significantly increasing adverse events.
Official title: The Analgesic Efficacy and Safety of Oral Medications (Desvenlafaxine) in Patients With Herpes Zoster
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
750
Start Date
2025-12-15
Completion Date
2027-12-31
Last Updated
2026-01-23
Healthy Volunteers
No
Conditions
Interventions
Desvenlafaxine combined conventional therapy
In the desvenlafaxine combined conventional therapy group, venlafaxine will be initiated at 50 mg daily. The maximum recommended dose is 400 mg daily. In addition, the group will contain conventional treatment for HZ, except desvenlafaxine, including NSAIDs, opioids, antiviral drugs and so on.
Conventional therapy
In the conventional therapy group, treatments will include NSAIDs, opioids, antiviral drugs and so on.
Locations (1)
Beijing Tiantan Hospital, Beijing, Beijing 100070
Beijing, China